Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer

Int J Mol Sci. 2023 Jan 4;24(2):910. doi: 10.3390/ijms24020910.

Abstract

Prostate cancer (PCa) is the most common male malignancy and the fifth leading cause of cancer death in men worldwide. Prostate cancer cells are characterized by a hybrid glycolytic/oxidative phosphorylation phenotype determined by androgen receptor signaling. An increased lipogenesis and cholesterogenesis have been described in PCa cells. Many studies have shown that enzymes involved in these pathways are overexpressed in PCa. Glutamine becomes an essential amino acid for PCa cells, and its metabolism is thought to become an attractive therapeutic target. A crosstalk between cancer and stromal cells occurs in the tumor microenvironment because of the release of different cytokines and growth factors and due to changes in the extracellular matrix. A deeper insight into the metabolic changes may be obtained by a multi-omic approach integrating genomics, transcriptomics, metabolomics, lipidomics, and radiomics data.

Keywords: androgen receptor; biomarkers; castration resistance; metabolomics; metastasis; prostate cancer.

Publication types

  • Review

MeSH terms

  • Humans
  • Male
  • Metabolomics
  • Oxidative Phosphorylation
  • Prostate / pathology
  • Prostatic Neoplasms* / metabolism
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism
  • Signal Transduction
  • Tumor Microenvironment

Substances

  • Receptors, Androgen

Grants and funding

This research received no external funding.